Comparing the current results to its competitors, Addex Therapeutics Ltd reported Revenue decrease in the 4 quarter 2025 year on year by -93.47 %, despite the revenue increase by the most of its competitors of 8.11 %, recorded in the same quarter.
Addex Therapeutics Ltd, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 73.47 %
Addex Therapeutics Ltd's Comment on Competition and Industry Peers
The company operates in the pharmaceutical industry, focusing exclusively on allosteric modulation drug discovery and development. All programs are developed in-house by experts. Its lead compound, dipraglurant, a metabotropic glutamate receptor subtype 5 negative allosteric modulator, is under evaluation for post-stroke and traumatic brain injury recovery. The company has an option and collaboration agreement with Sinntaxis AB for an exclusive license. The competitive landscape includes challenges related to patent protection and competitors' ability to design around patents. Competitors identified include Sinntaxis AB.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Kiniksa Pharmaceuticals International Plc Share Performance
+82.07%
This Year
Kiniksa Pharmaceuticals International Plc
Profile
Kiniksa Pharmaceuticals Ltd is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with debilitating diseases and unmet medical needs. Their business model revolves around identifying potential drug candidates, conducting rigorous research and development, and ultimately bringing these drugs to market to provide innovative treatment options. They generate revenue through the sale of their products and collaborations with other companies for the development and commercialization of their therapies.
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
Sources:
Addex Therapeutics Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Addex Therapeutics Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
